Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
3/8/2012 6:10:54 AM
MALVERN, Penn.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that the United States Food and Drug Administration (FDA) Office of Orphan Products Development has granted an Orphan Drug designation to Promedior’s lead drug candidate, PRM-151, for the treatment of idiopathic pulmonary fibrosis (IPF). There are currently no FDA approved treatments for IPF, a progressive, debilitating and fatal disease that affects approximately 200,000 people in Europe and the United States combined.
comments powered by